These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 30643381)
1. Safety and efficacy of twice daily administration of KPI-121 1% for ocular inflammation and pain following cataract surgery. Kim T; Sall K; Holland EJ; Brazzell RK; Coultas S; Gupta PK Clin Ophthalmol; 2019; 13():69-86. PubMed ID: 30643381 [TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery. Comstock TL; Paterno MR; Singh A; Erb T; Davis E Clin Ophthalmol; 2011; 5():177-86. PubMed ID: 21383946 [TBL] [Abstract][Full Text] [Related]
3. Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two Phase III clinical studies. Fong R; Cavet ME; DeCory HH; Vittitow JL Clin Ophthalmol; 2019; 13():1427-1438. PubMed ID: 31447544 [TBL] [Abstract][Full Text] [Related]
4. Loteprednol etabonate ophthalmic gel 0.5% following cataract surgery: integrated analysis of two clinical studies. Rajpal RK; Fong R; Comstock TL Adv Ther; 2013 Oct; 30(10):907-23. PubMed ID: 24136301 [TBL] [Abstract][Full Text] [Related]
5. Safety of KPI-121 Ophthalmic Suspension 0.25% in Patients With Dry Eye Disease: A Pooled Analysis of 4 Multicenter, Randomized, Vehicle-Controlled Studies. Korenfeld M; Nichols KK; Goldberg D; Evans D; Sall K; Foulks G; Coultas S; Brazzell K Cornea; 2021 May; 40(5):564-570. PubMed ID: 32826644 [TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects. Comstock TL; Paterno MR; Bateman KM; Decory HH; Gearinger M Paediatr Drugs; 2012 Apr; 14(2):119-30. PubMed ID: 22292487 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery. Rajpal RK; Roel L; Siou-Mermet R; Erb T J Cataract Refract Surg; 2013 Feb; 39(2):158-67. PubMed ID: 23218817 [TBL] [Abstract][Full Text] [Related]
8. Submicron loteprednol etabonate ophthalmic gel 0.38% for the treatment of inflammation and pain after cataract surgery. Fong R; Silverstein BE; Peace JH; Williams JI; Vittitow JL J Cataract Refract Surg; 2018 Oct; 44(10):1220-1229. PubMed ID: 30193927 [TBL] [Abstract][Full Text] [Related]
9. Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial. Fong R; Leitritz M; Siou-Mermet R; Erb T Clin Ophthalmol; 2012; 6():1113-24. PubMed ID: 22888209 [TBL] [Abstract][Full Text] [Related]
10. KPI-121 1% for pain and inflammation in ocular surgery. Beckman KA; Katz JA; Majmudar PA; Rips AG; Vaidya NS; Rostov AT Pain Manag; 2022 Jan; 12(1):17-23. PubMed ID: 34164994 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children. Silverstein BE; Allaire C; Bateman KM; Gearinger LS; Morris TW; Comstock TL Clin Ther; 2011 Jan; 33(1):13-26. PubMed ID: 21397770 [TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of bromfenac ophthalmic solution (Bromday) dosed once daily for postoperative ocular inflammation and pain. Henderson BA; Gayton JL; Chandler SP; Gow JA; Klier SM; McNamara TR; Ophthalmology; 2011 Nov; 118(11):2120-7. PubMed ID: 21762992 [TBL] [Abstract][Full Text] [Related]
14. A randomized double-masked study to compare the ocular safety, tolerability, and efficacy of bromfenac 0.075% compared with vehicle in cataract surgery subjects. Hosseini K; Walters T; DaVanzo R; Lindstrom RL Clin Ophthalmol; 2016; 10():2311-2317. PubMed ID: 27920490 [TBL] [Abstract][Full Text] [Related]
15. Nepafenac dosing frequency for ocular pain and inflammation associated with cataract surgery. Maxwell WA; Reiser HJ; Stewart RH; Cavanagh HD; Walters TR; Sager DP; Meuse PA J Ocul Pharmacol Ther; 2008 Dec; 24(6):593-9. PubMed ID: 19040348 [TBL] [Abstract][Full Text] [Related]
16. Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%: A Review in Post-Operative Inflammation and Pain Following Ocular Surgery. Kang C; Keam SJ; Shirley M; Syed YY Clin Drug Investig; 2020 Apr; 40(4):387-394. PubMed ID: 32172521 [TBL] [Abstract][Full Text] [Related]
17. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. The Loteprednol Etabonate Postoperative Inflammation Study Group 2. Ophthalmology; 1998 Sep; 105(9):1780-6. PubMed ID: 9754192 [TBL] [Abstract][Full Text] [Related]
18. Loteprednol etabonate ophthalmic gel 0.5%: a review of its use in post-operative inflammation and pain following ocular surgery. Lyseng-Williamson KA Drugs; 2013 Jun; 73(9):949-58. PubMed ID: 23740411 [TBL] [Abstract][Full Text] [Related]
19. Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1. Stewart R; Horwitz B; Howes J; Novack GD; Hart K J Cataract Refract Surg; 1998 Nov; 24(11):1480-9. PubMed ID: 9818338 [TBL] [Abstract][Full Text] [Related]
20. OCS-01 (Novel Topical Dexamethasone Formulation) in Inflammation and Pain Post Cataract Surgery: A Randomized, Double-Masked, Vehicle-Controlled Study. Korenfeld M; Gira J; Jong K; Martel J; Vold S; Walters T; Usner D; Donnenfeld E Clin Ther; 2022 Dec; 44(12):1577-1587. PubMed ID: 36503736 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]